期刊文献+

胰岛素抵抗与前列腺增生的相关性研究 被引量:2

The association between insulin resistance and prostatic hyperplasia
原文传递
导出
摘要 目的探讨胰岛素抵抗与良性前列腺增生(BPH)发生发展的相关性。方法纳人我院老年科住院的男性患者150例。测量血压、身高、体质量、计算体质指数(BMI)。并检测空腹胰岛素(FINS)、空腹血糖、胰岛素抵抗指数(HOMA-IR)、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和前列腺特异性抗原(PsA)。超声测量及计算前列腺体积(PV)。结果胰岛素抵抗组(40例)患者PV和PV年增长率明显大于胰岛素敏感组(110例)患者(t=2.91,3.71;均P〈0.01)。随着患者FINS、HOMA—IR、PSA的增加,PV增大(t值分别为-3.02、-2.88、-2.84;均P〈O.05)。PV与胰岛素抵抗、FINS、PSA呈正相关(r分别为0.16,0.16,0.35;均P〈0.05);PV年增长率与胰岛素抵抗、FINS、PSA、BMI成正相关(r分别为0.22,0.21,0.24,0.19;均P〈0.05)。结论胰岛素抵抗和高FINS是BPH发生发展的危险因素。 Objective To evaluate the relationship between insulin resistance and benign prostatic hyperplasia (BPH). Methods Totally 150 male patient from the Department of Geriatrics in Peking University Hospital were included in this study. Blood pressure, body weight, body height, body mass index (BMI) were measured and calculated. Biochemical analyses including serum fasting levels of insulin(FINS), glucose, total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and prostate-specific antigen (PSA) were performed. Total prostate volume (PV) were measured by ultrasound. Results PV and annual prostate growth rate were more increased in insulin resistance group( 40 cases) compared with insulin sensitivity group(110 cases) (t=2.91, 3.71 respectively, both P(0.01). Along with the levels of FINS, HOMA-IR and PSA were increased, the prostate volume was enhanced (t = 3.02, - 2.88, -- 2.84 respectively all P d0.05). PV was positively correlated with insulin resistance, serum fasting insulin and PSA (r= 0.16, 0.16, 0.35;all P〈0.05), while annual prostate growth rate was positively related with insulin resistance, serum fasting insulin, PSA and BMI (r= 0.22, 0.21, 0.24, 0.19; all P〈0.05). Conclusions Insulin resistance and fasting insulin plays roles in the pathogenesis of prostatic hyperplasia.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2012年第10期840-842,共3页 Chinese Journal of Geriatrics
关键词 前列腺增生 胰岛素抵抗 空腹胰岛素 Prostatic hyperplasia Insuline resistance Fasting insulin
  • 相关文献

参考文献13

  • 1Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol, 2001, 39= 151-158.
  • 2Dahle SE, Chokkalingam AP, Gao YT, et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol, 2002, 168:599 604.
  • 3Sourij H, Schmoelzer I, Dittrich P, et al. Insulin resistance as a risk factor for carotid atherosclerosis: a comparison of the homeostasis model assessment and the short insulin tolerance test. Stroke,2008, 39: 1349-1351.
  • 4OzdenC, Ozdal O, Urgancioglu G, et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol, 2007, 51: 199-206.
  • 5贾伟平.中国人群胰岛素抵抗的状况[J].国外医学(内分泌学分册),2002,22(4):264-264. 被引量:104
  • 6刘颖,屈晓冰,董莉妮,沈芳.老年人良性前列腺增生症与胰岛素抵抗[J].中华老年医学杂志,2010,29(11):896-898. 被引量:12
  • 7OzdenC, Ozdal OL, Urqancioqiu G, et al. The correlation between metabolic syndrom and prostatic growth in patients with benign prostata hyperplasie. Eur Urol, 2007, 51199 203.
  • 8姚麒,余晶波.代谢综合征与前列腺增生的相关性研究[J].中华老年医学杂志,2012,31(1):61-62. 被引量:3
  • 9Nandeesha H, Kone BC, Dorairajan LN. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clinica Chimica Acta, 2006,370:89-93.
  • 10Parsons JK,Carter HB,Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab,2006, 91 : 2562-2568.

二级参考文献24

  • 1中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中国糖尿病杂志,2004,12(3):156-161. 被引量:3053
  • 2Nandeesha H, Koner BC, Dorairajan LN, et al. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clinica Chimica Acta, 2006,370:89-93.
  • 3Deborah AF, Jamie LW, I.awrence MD, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes. J Pediatr, 2007,151:653-658.
  • 4HammastenJ, Hogsted B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol,2001,39: 151-158.
  • 5OzdenC, Ozdal OL, Urgancioglu G, et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol,2007,51: 199-206.
  • 6Burke JP,Jacobson DJ, Mcgree ME, et al. Diabetes and benign prostatic hyperplasia progression in Olmsted county, Minnesota. Urology, 2006, 67: 22-25.
  • 7Hammarsten J, Hogstedt B gstedt. Calculated fast-growing benign prostatic hyperplasia: A risk factor for developing clinical prostate cancer. Scand J Urol Nephrol, 2002, 36: 330-338.
  • 8McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 2003, 349:2387-2398.
  • 9Eckel RH. Grundy SM, Zimmel PZ. The metabolic syndrome. Lancet,2005,365:1415-1428.
  • 10Whcatcroft SB, Williams IL, Shah AM, et al. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med, 2003,20: 255-268.

共引文献124

同被引文献20

  • 1Kwon H, Kang HC, Lee JH. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms [J]. Urology, 2013,81:1325-1329.
  • 2Nandeesha H, Koner BC, Dorairajan LN, et al. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta, 2006, 370:89-93.
  • 3Mills IW, Crossland A, Patel A, et al. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement [J]. Eur Urol, 2007, 52:503-509.
  • 4Ozden C, Ozdal OL, Urgancioglu G, et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia [J]. EurUrol, 2007, 51:199-203, 204-206.
  • 5RohrmannS, Smit E, Giovannucci E, et al. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III ). Int J Obes (Lond), 2005, 29: 310-316.
  • 6Hamilton RJ, Goldberg KC, Platz EA, et al. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst, 2008, 100: 1511-1518.
  • 7Fowke JH, Motley SS, Barocas DA, et al. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer [J]. Cancer Causes Control, 2011, 22: 417-426.
  • 8St Sauver JL, Jacobsen SJ, Jacobson DJ, et al. Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms[J]. BJU Int, 2011, 107:443-450.
  • 9Hall SA, Chiu GR, Link CL, et al. Are statin medications associated with lower urinary tract symptoms in men and women? Results from the Boston Area Community Health (BACH) Survey[J]. Ann Epidemiol, 2011, 21: 149-155.
  • 10Stamatiou KN, Zaglavira P, Skolarikos A, et al. The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride[J]. Int Braz J Urol, 2008, 34:555-562.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部